Optimizing Treatment for Relapsed Refractory Follicular Lymphoma and Marginal Zone Lymphoma

Alexey Danilov, MD, and Tycel Jovelle Phillips, MD, provide insight on common signs and symptoms of follicular lymphoma (FL) and factors to consider when selecting first-line therapy.

Tycel Jovelle Phillps, MD, shares second-line treatment approaches for the management of follicular lymphoma and examines the use of PI3K inhibitors.

Dr Alexey Danilov reviews the 2-year follow-up of the phase 2 CHRONOS-1 study evaluating the use of copanlisib monotherapy in relapsed/refractory follicular lymphoma.

Expert hematologist-oncologists examine the use of tazemetostat based on a phase 2 trial for relapsed/refractory follicular lymphoma and consider clinical implications.

Dr Tycel Jovelle Phillips reviews key ongoing trials in relapsed/refractory follicular lymphoma.

Tycel Jovelle Phillips, MD, and Alexey Danilov, MD, share insights on common signs and symptoms of marginal zone lymphoma and approaching initial therapy.

Experts in hematology/oncology discuss second-line and beyond treatment options for patients with MZL and comment on copanlisib monotherapy for the management of R/R MZL as seen in the phase 2 CHRONOS-1 study.

Tycel Jovelle Phillips, MD, discusses recent updates from the CHRONOS-3 trial of copanlisib in R/R MZL and clinical implications of the results of this study.

Alexey Danilov, MD, and Tycel Jovelle Phillips, MD, discuss strategies for selecting the appropriate treatment for patients with relapsed/refractory marginal zone lymphoma.

Drs. Alexey Danilov and Tycel Jovelle Phillips share insight on emerging agents and future directions for the management of marginal zone lymphoma.